Human trial of 'COVAXIN' begins in AIIMS
Human trial of 'COVAXIN' begins in AIIMS
Share:

New Delhi: The first phase of the human trial of 'COVAXIN', the country's first indigenously developed vaccine for the prevention of coronavirus, has started in AIIMS on Friday. A person between 30 and 40 years of age was given the first injection. More than 3,500 people have registered themselves for testing at AIIMS since last Saturday, out of which at least 22 screenings are going on. Dr Sanjay Rai, Professor and Chief officer of Community Medical Center at AIIMS has given information in this regard.

Rai has said that "The first person from Delhi was examined two days ago and all his health criteria were found to be correct. He does not have any other disease. The first dose of 0.5 ml of the vaccine by injection was given to him around 1.30 pm. No side effects have been seen so far. He is under surveillance for two hours and will be monitored for the next seven days.''

Indian Council of Medical Research (ICMR) has identified 12 institutes including AIIMS for the first and second phase clinical trials of 'COVAXIN'. In the first phase, 375 people will be tested and the maximum of them can be 100. According to Rai, the second phase will comprise a total of around 750 people from all the 12 institutions. In the first phase, the vaccine will be tested on healthy people between 18 and 55 years of age who do not have any other disease.

This famous leader openly spoke against President Xi Jinping

US accuses China of hiding Scientist wanted by FBI in San Francisco

Kamal Nath attacks Shivraj government, says "At least provide treatment to poor section"

Join NewsTrack Whatsapp group
Related News